Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Distribution agreement for Genesis products

16 Jul 2009 07:00

RNS Number : 7478V
Omega Diagnostics Group PLC
16 July 2009
 



AIM: ODX

Omega Diagnostics Group PLC ('Omega')

UK Distribution agreement for Genesis products 

Omega, the AIM listed medical diagnostics company, announces that its UK-based subsidiary, Genesis Diagnostics Ltd ('Genesis') has signed an exclusive distribution agreement with Biohit Healthcare Ltd ('Biohit'), the UK-based subsidiary of Biohit Oyj, a Finnish public company which develops, manufactures and markets liquid handling products and diagnostic test systems for use in research, health care and industrial laboratories.

Biohit will take on the UK distribution and servicing of the Genesis product range using their UK-wide sales force and will offer complete coverage of the UK NHS hospital network. Both companies are committed to maintaining and improving upon the high level of customer service provided by Genesis. Biohit already services many current Genesis customers and the customer base is expected to expand as a result of this agreement.

Andrew Shepherd, Chief Executive of Omega, said, "The synergy between Genesis and Biohit is clear in that both companies service the same clinical laboratory market with complementary products. The UK market for clinical diagnostic products is highly competitive and we need to have a full scale sales force that can operate across the UK and increase our business base going forward. Using Biohit provides us with access to a much enlarged customer base and allows our resources to be focussed on other growth areas in the UK and beyond."

 

Richard Vaughton, Managing Director of Biohit commented, "The addition of Genesis products enhances the offering to our current customer base and helps focus our sales drive in the clinical laboratory market. We look forward to providing an excellent service to existing Genesis customers, many of whom we are familiar with, and to winning many new customers."

Further enquiries:

Omega Diagnostics Group PLC:

Tel: 01259 763 030

Andrew Shepherd, Chief Executive

Kieron Harbinson, Finance Director

www.omegadiagnostics.com

Cenkos Securities plc

Tel : 020 7397 8900

Nick Wells, Andy Roberts, Elizabeth Bowman

ebowman@cenkos.com

Walbrook PR Limited

Tel : 020 7933 8787

Paul McManus

Mob : 07980 541 893

paul.mcmanus@walbrookpr.com

Information on Biohit Oyj

Biohit Oyj, a Finnish Public company, develops, manufactures and markets liquid handling products and diagnostic test systems for use in research, health care and industrial laboratories.

Established in 1988, Biohit Oyj is headquartered in Finland. Biohit has subsidiaries in FranceGermany, the UKRussiaChinaJapan and the USA. Additionally, Biohit's products are sold by approximately 450 distributors in 70 countries. Biohit Oyj had net sales of 35.1M euros in 2008 and employed 370 personnel. 

Geographically sales are split as follows: Europe: 55.6%North & South America 18.1%Asia 11.5%Other Countries 14.8%

Biohit's shares (BIOBV) are quoted on NASDAQ OMX Helsinki. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRBLGDRBBBGGCU
Date   Source Headline
16th Sep 202211:13 amRNSPurchase of Shares by Directors
13th Sep 20227:00 amRNSInvestor presentation and Confirmation of AGM
12th Sep 20227:00 amRNSFinal Results
2nd Sep 202210:15 amRNSHolding(s) in Company
31st Aug 20227:00 amRNSChange of preliminary results date
12th Aug 20227:00 amRNSChange of preliminary results date
8th Aug 20227:00 amRNSConfirmation of Preliminary Results
5th Aug 202212:09 pmRNSHolding(s) in Company
3rd Aug 20227:00 amRNSCompletion of Sale of the CD4 Business
11th Jul 20227:00 amRNSPayment received
4th Jul 20227:00 amRNSHeads of Terms agreed for Sale of CD4 Business
23rd Jun 20223:13 pmRNSHolding(s) in Company
10th Jun 20227:00 amRNSGrant of share incentive awards
8th Jun 20221:47 pmRNSPDMR/Director Dealing
6th Jun 20222:29 pmRNSResult of General Meeting and Total Voting Rights
1st Jun 20227:00 amRNSResult of Open Offer
13th May 202210:05 amRNSPosting of Circular and Notice of General Meeting
11th May 20223:28 pmRNSHolding(s) in Company
6th May 20227:01 amRNSInvestor presentation
6th May 20227:00 amRNSPlacing, Subscription and Open Offer
7th Apr 20227:00 amRNSTrading Update
11th Mar 20227:00 amRNSUpdate on validation under CTDA legislation
8th Mar 20224:41 pmRNSSecond Price Monitoring Extn
8th Mar 20224:36 pmRNSPrice Monitoring Extension
7th Mar 20224:41 pmRNSSecond Price Monitoring Extn
7th Mar 20224:36 pmRNSPrice Monitoring Extension
7th Mar 20223:40 pmRNSResult of General Meeting
7th Mar 202211:03 amRNSConfirmation of Sale of Alva business
1st Mar 20227:00 amRNSResult of Open Offer
18th Feb 20227:00 amRNSInvestor Meeting
14th Feb 20222:06 pmRNSSecond Price Monitoring Extn
14th Feb 20222:01 pmRNSPrice Monitoring Extension
11th Feb 202211:05 amRNSSecond Price Monitoring Extn
11th Feb 202211:00 amRNSPrice Monitoring Extension
11th Feb 20227:01 amRNSFundraising to raise gross proceeds of up to £7m
11th Feb 20227:00 amRNSSale of Alva manufacturing business
10th Feb 20222:06 pmRNSSecond Price Monitoring Extn
10th Feb 20222:00 pmRNSPrice Monitoring Extension
10th Feb 20221:33 pmRNSSpeculation regarding a potential fundraise
8th Feb 20224:41 pmRNSSecond Price Monitoring Extn
8th Feb 20224:36 pmRNSPrice Monitoring Extension
3rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20224:36 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSCE-Mark for self-test for VISITECT® COVID-19 test
2nd Feb 20224:41 pmRNSSecond Price Monitoring Extn
2nd Feb 20224:36 pmRNSPrice Monitoring Extension
31st Jan 20227:00 amRNSSpeculation regarding a potential fundraise
19th Jan 20227:00 amRNSDirectorate Change
10th Jan 20223:20 pmRNSConfirmation of detection of Omicron variant
4th Jan 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.